Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer.

Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen

NCT05731258 ·Status: RECRUITING

Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

NCT05287308 ·Status: NOT_YET_RECRUITING ·Phase: NA

Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients

NCT03123770 ·Status: UNKNOWN ·Phase: PHASE4

Neoadjuvant Chemotherapy With a Combination of Pegylated Liposomal Doxorubicin (Caelyx®) and Paclitaxel in Breast Cancer

NCT03221881 ·Status: COMPLETED ·Phase: NA

Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer

NCT05251766 ·Status: UNKNOWN ·Phase: PHASE1

Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer

NCT00296010 ·Status: TERMINATED ·Phase: PHASE3

Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

NCT04193059 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

NCT05159193 ·Status: RECRUITING ·Phase: PHASE3

AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer

NCT05302336 ·Status: UNKNOWN ·Phase: PHASE4

Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)

NCT03949634 ·Status: UNKNOWN ·Phase: PHASE3

Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy

NCT01019616 ·Status: UNKNOWN ·Phase: PHASE3

Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer

NCT02613026 ·Status: COMPLETED ·Phase: PHASE3

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

NCT04836156 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer

NCT07093931 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

NCT04126525 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy

NCT04137640 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

NCT03735966 ·Status: COMPLETED ·Phase: PHASE2

AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer

NCT01415336 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index

NCT05728268 ·Status: RECRUITING ·Phase: PHASE2

Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer

NCT00290732 ·Status: COMPLETED ·Phase: PHASE1

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

NCT00436709 ·Status: UNKNOWN ·Phase: NA

Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer

NCT02041338 ·Status: UNKNOWN ·Phase: PHASE2

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

NCT03628066 ·Status: COMPLETED ·Phase: PHASE2

Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer

NCT01479036 ·Status: UNKNOWN ·Phase: PHASE3

Neoadjuvant Effect of Albumin Binding Paclitaxel Compared With Common Paclitaxel in Breast Cancer：an Observational Single Center Study of Clinical Efficacy in Adjuvant Chemotherapy

NCT05636644 ·Status: UNKNOWN